A multi-center study of high dose Aldesleukin (Proleukin® (HD IL-2) + Vemurafenib Zelboraf® ) therapy in patients with BRAFV600 mutation positive metastatic melanoma (proclivity 01)

A multi-center study of high dose Aldesleukin (Proleukin® (HD IL-2) + Vemurafenib Zelboraf® ) therapy in patients with BRAFV600 mutation positive metastatic melanoma (proclivity 01)

Bibliographic Details
Main Authors:	Clark, Joseph, Flaherty, Lawrence, Ernstoff, Marc, Koon, Henry, Milhem, Mohammed, Militello, Gerald, Agarwala, Sanjiv, Curti, Brendan, Cranmer, Lee, Lao, Christopher D, Logan, Theodore F, Lutzky, Jose, Rudrapatna, Venkatesh, Daniels, Gregory, Taback, Bret, Aung, Sandra, Lowder, James, Lawson, David
Format:	Online
Language:	English
Published:	BioMed Central 2014
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288741/

Similar Items

Open-label, randomized, multi-center study comparing the sequence of high dose Aldesleukin (Proleukin® (HD IL-2) and Ipilimumab Yervoy® ) in patients with metastatic melanoma (proclivity 02)
by: Patel, Sapna, et al.
Published: (2014)

A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma
by: Joseph I. Clark, et al.
Published: (2018-07-01)

The genesis of Zelboraf: Targeting mutant B-Raf in melanoma
by: Davis, Matthew J., et al.
Published: (2012)

Vemurafenib enhances MHC induction in BRAFV600E homozygous melanoma cells
by: Sapkota, Bishu, et al.
Published: (2013)

Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent
by: del Bufalo, Francesca, et al.
Published: (2014)

Racial Proclivities to Disease
Published: (1909)

Update on use of aldesleukin for treatment of high-risk metastatic melanoma
by: Amaria, Rodabe N, et al.
Published: (2015)

Membrane Stress Proclivities in the Mammalian Labyrinth
by: Pender, Daniel J.
Published: (2014)

S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAFV600E/Mt to Vemurafenib
by: Xuelong Jiao, et al.
Published: (2018-09-01)

The clinical response to vemurafenib in a patient with a rare BRAFV600DK601del mutation-positive melanoma
by: Trudel, Stéphanie, et al.
Published: (2014)

Prakruti genomics and prameha-proclivity: relevance to metabolic syndrome
by: Vaidya, Ashok DB
Published: (2014)

Proclivity of political participation among Wakaidesu (????) Japanese
by: Part Time Mohd Zulhimi bin Zolkefali
Published: (2017)

Cultural background shapes spatial reference frame proclivity
by: Goeke, Caspar, et al.
Published: (2015)

The Proclivity of Women to Cancerous Diseases, and to Certain Benign Tumours
Published: (1892)

Correlates of academic misconduct and CSR proclivity of students
by: Stephen, K. Nkundabanyanga, et al.
Published: (2014)

coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAFV600 mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519)
by: Ascierto, Paolo A, et al.
Published: (2015)

FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973
by: Baudy, Andreas R, et al.
Published: (2012)

Scurvy in a patient on vemurafenib
by: Gerstenblith, Meg R., et al.
Published: (2014)

Dietary proclivities of Paranthropus robustus from Swartkrans, South Africa
by: L’Engle Williams Frank
Published: (2015-03-01)

Inherited proclivity: When should neurogenetics mitigate moral culpability for purposes of sentencing?
by: Segal, J Bradley
Published: (2016)

Effects of relational proclivity and marketing intelligence on new product development
by: Kevin, J. Trainor, et al.
Published: (2013)

Metastatic melanoma and vemurafenib: novel approaches
by: De Mello, Ramon Andrade
Published: (2012)

A STATement on Vemurafenib-Resistant Melanoma
by: Hartsough, Edward J., et al.
Published: (2013)

Complete remission of critical neurohistiocytosis by vemurafenib
by: Euskirchen, Philipp, et al.
Published: (2015)

Stable disease after high dose interleukin-2 (HD IL-2) immunotherapy: observations on long term survival and clinical benefit of additional HD IL-2
by: Kaufman, Howard L, et al.
Published: (2014)

A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma
by: Buchbinder, Elizabeth I., et al.
Published: (2016)

BRAFV600E protein expression and outcome from BRAF inhibitor treatment in BRAFV600E metastatic melanoma
by: Wilmott, J S, et al.
Published: (2013)

Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model
by: Duquette, Mark, et al.
Published: (2015)

Updated results and correlative FDG-PET analysis of a phase IB study of vemurafenib and cobimetinib (MEK inhibitor [GDC-0973]), in advanced BRAFV600- mutated melanoma (BRIM7)
by: Puzanov, Igor, et al.
Published: (2014)

Correction: RASopathic Skin Eruptions during Vemurafenib Therapy
by: Rinderknecht, Jeannine D., et al.
Published: (2013)

Safety and efficacy of vemurafenib in end stage renal failure
by: Iddawela, Mahesh, et al.
Published: (2013)

RASopathic Skin Eruptions during Vemurafenib Therapy
by: Rinderknecht, Jeannine D., et al.
Published: (2013)

Managing Side Effects of Vemurafenib Therapy for Advanced Melanoma
by: Hagen, Brenda, et al.
Published: (2014)

Vemurafenib and cutaneous adverse events - report of five cases*
by: Silva, Giselle de Barros, et al.
Published: (2015)

DNA repair inhibition by UVA photoactivated fluoroquinolones and vemurafenib
by: Peacock, Matthew, et al.
Published: (2014)

Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma
by: Fofaria, Neel M., et al.
Published: (2015)

Tribal proclivity and its effects on the cooperate existence of Nigeria in the centenary era: an Islamic perspective
by: Muhammad, Usman Jimoh
Published: (2015)

Tribal proclivity and its effects on the cooperate existence of Nigeria in the centenary era: an Islamic perspective
by: Nik Zainun
Published: (2015)

Insecure Attachment Style and Dysfunctional Sexual Beliefs Predict Sexual Coercion Proclivity in University Men
by: Dang, Silvain S, et al.
Published: (2015)

Inflammasome effects in GvHD
by: Koehn, Brent H., et al.
Published: (2015)